Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial - The Clinical Trial Vanguard

Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial  The Clinical Trial VanguardDaily pill doubles survival time for pancreatic cancer patients  BBCExperimental pill promises new hope for deadly pancreatic cancer  The HinduDaily pill can double survival time for world’s deadliest cancer, trial shows  The Guardian‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long  The Washington Post